Pelvital USA, Inc. is a women’s health medical device company based in Eagan, Minnesota, led by President and CEO Lydia Zeller. Its first product, Flyte, is an FDA-cleared, novel in-home treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles that delivers mechanotherapy to the pelvic floor. Flyte is reported effective for mild, moderate, and severe SUI, with a typical treatment regimen of five minutes per day for six weeks. The company positions Flyte as a convenient, clinician-backed pelvic floor therapy that can be used outside clinical settings. Pelvital recently closed an additional $2.32M in a seed-plus financing to accelerate commercialization of Flyte. Pelvital, based in Eagan, MN, develops Flyte, an FDA-cleared at-home intravaginal device that delivers mechanotherapy to treat stress urinary incontinence (SUI) and strengthen pelvic floor muscles. Flyte’s mechanism pairs mechanotherapy with an active pelvic floor contraction to stimulate tissue repair and create neuromuscular memory. The device was originally developed by physicians from the Arctic University of Norway with collaborators in gynecology, muscle rehabilitation, and urinary incontinence treatment. Pelvital is led by President and CEO Lydia Zeller. The company recently closed a $2.68M seed funding round, providing capital to complete development of its next-generation product. Management plans to use the proceeds to accelerate commercialization and expand reach to clinicians and women seeking conservative, in‑home SUI treatment.

Total raised

$5M

Funding rounds

2

Latest round

Seed

Latest activity

Apr 2024